Replies to post #162931 on Biotech Values

[DewDiligence]

PLX/KMDA—…since I don't recall safety problem with any plasma derived AAT, I don't think this argument [by PLX] is strong enough to break orphan exclusivity.

If I recall correctly, we had this discussion a few years ago and reached the same conclusion.